title: [Clinical analyses of oral squamous cell carcinoma patients showing a complete response to chemotherapy with S-1 alone].
abstract: The purpose of this study was to investigate the effectiveness and safety of palliative chemotherapy using S-1 alone. We clinically analyzed 8 oral squamous cell carcinoma patients showing a complete response(CR)to chemotherapy with S-1 alone. These patients received chemotherapy consisting of 2 weeks' administration, including 5-days' administration and 2- days' termination, following a 1-week rest. Adverse effects were observed in 4 patients. However, all of them were grade 1 toxicities. The average length of S-1 administration before achieving CR was 9. 8 ± 3. 1 weeks(3. 3 ± 1. 0 courses). Seven patients had a recurrence. The prognosis of this group was 5 deaths by local recurrence, and 1 death by lymph node metastasis. The average length of disease progression was 447. 4 ± 479. 5 days. Two patients, one who received surgery and the other who received irradiation after chemotherapy by S-1, are alive without tumors. The 1-year and 3-year disease-free survival rates were 100% and 37. 5%, respectively.
authors.affiliation: Dental and Oral Medical Center, Kurume University School of Medicine, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Nakamura
authors.forename: Makoto
authors.initials: M
authors.lastname: Koga
authors.forename: Masatora
authors.initials: M
authors.lastname: Aoki
authors.forename: Osamu
authors.initials: O
authors.lastname: Iwamoto
authors.forename: Chihiro
authors.initials: C
authors.lastname: Koga
authors.forename: Jingo
authors.initials: J
authors.lastname: Kusukawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid